Comparison of trastuzumab plus capecitabine combination therapy (HX therapy) and lapatinib plus capecitabine combination therapy (LX therapy) in HER2 positive metastatic or unresectable locally advanced breast cancer with history of trastuzumab and taxane anticancer drugs Randomized comparison II Exploratory study of effect predictors in phase test

Trial Profile

Comparison of trastuzumab plus capecitabine combination therapy (HX therapy) and lapatinib plus capecitabine combination therapy (LX therapy) in HER2 positive metastatic or unresectable locally advanced breast cancer with history of trastuzumab and taxane anticancer drugs Randomized comparison II Exploratory study of effect predictors in phase test

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presente at the 39th Annual San Antonio Breast Cancer Symposium..
    • 08 Jan 2015 New trial record
    • 13 Feb 2014 Planned number of patients changed from 170 to 110 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top